The Cosentyx Drug Market refers to the commercial ecosystem around secukinumab — an IL-17A monoclonal antibody marketed by Novartis under the brand name Cosentyx — including its clinical uses, regulatory approvals, manufacturing and supply, pricing and reimbursement, distribution channels (retail and hospital pharmacies), and competitive dynamics with other biologics and biosimilars. ... https://www.metatechinsights.com/industry-insights/cosentyx-drug-market-2393